AI-generated analysis. Always verify with the original filing.
Celldex Therapeutics entered into an underwriting agreement to sell 10,345,000 shares of common stock at $29.00 per share, with expected net proceeds of approximately $282 million, to fund commercial readiness, clinical development, and general corporate purposes.
Celldex Therapeutics has initiated a significant capital raise through a public offering of common stock, aiming to secure approximately $282 million in net proceeds. This financing is structured as a firm commitment underwriting led by Leerink Partners and TD Securities, with the potential for additional capital through a 30-day over-allotment option. The primary strategic use of proceeds is clearly directed toward advancing the company's lead asset, barzolvolimab, specifically for commercial readiness and potential launch for chronic spontaneous urticaria (CSU) treatment, contingent upon regulatory approval. Furthermore, the capital is earmarked to sustain the broader clinical and preclinical pipeline, including the development of barzolvolimab in other indications and the expansion of the company's bispecific antibody platform. The transaction is expected to close shortly, providing the company with substantial liquidity to execute its near-term strategic objectives without immediate reliance on future financing, thereby reducing near-term dilution risk for existing shareholders.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement.** On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwri
Other Events.** On April 1, 2026, the Company issued a press release regarding the launch of the Offering. On April 1, 2026, the Company also issued a press rel
Financial Statements and Exhibits.** ** (d) Exhibits. ** | Exhibit No. | | Description | |---|---|---| | 1.1 | | Underwriting Agreement, dated April 1, 2026, by
Material Agreement